NCT07173660Not yet recruiting
Consensus Statements on Deep Brain Stimulation in Patients With Parkinson's Disease
Consensus Statements on Deep Brain Stimulation in Patients With Parkinson's Disease - A Delphi Study
Source: ClinicalTrials.gov · Last updated 23 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Deep brain stimulation (DBS) has become a cornerstone therapy for advanced Parkinson's disease (PD), showing superior outcomes over best medical treatment in randomized clinical trials. By delivering adjustable electrical stimulation to key basal ganglia targets, DBS improves tremor, rigidity, bradykinesia, and motor fluctuations, while also reducing dopaminergic medication requirements. Its success, however, depends not only on precise surgical targeting but also on careful patient selection, multidisciplinary planning, and structured long-term follow-up. In Italy, PD affects nearly 176,000 individuals, of whom an estimated 2-4.5% are potential candidates for DBS. A national survey conducted by the Italian Neurosurgery Society (SINch) revealed marked heterogeneity in surgical approaches, target selection, and team composition across DBS centers-reflecting similar international variability. Yet, clear national indications and guidelines have not been established. To address this gap, we conducted an expert consensus using the Delphi methodology.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 30 (estimated)
- First submitted
- 7 Sept 2025
- Start date
- 15 Sept 2025
- Primary completion date
- 15 Nov 2025
- Lead sponsor
- University Magna Graecia
- Diseases
- Parkinson disease
- NCT number
- NCT07173660
What you commit to
- Study type: Observational
- Planned participants: 30
- From 15 Sept 2025 to the primary completion date, 15 Nov 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- \- Purposive sampling will be applied to identify Italian panelists, primarily through a review of recent publications in the field of DBS for Parkinson's disease. Panelist selection will adhere to the predefined criteria, with deliberate efforts to ensure gender balance and broad geographical representation across Italy.
Other
- \- None.
- Recruitment strategy:
Who the study is looking for
- At least 5 years of clinical experience in the care of patients with Parkinson's disease, including involvement in deep brain stimulation (DBS) implantation (in both teaching and non-teaching settings).
- Prior participation in guideline development or authorship of at least one peer-reviewed publication on neuromodulation in Parkinson's disease.
Criteria the registry did not label
- Panelist selection
- Healthcare professionals will be recruited as panelists based on the following predefined criteria:
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.